Urogen Pharma (($URGN)) announced an update on their ongoing clinical study. Study Overview: UroGen Pharma is conducting a Phase 3 study titled ‘A ...

ZUSDURI (mitomycin) for intravesical solution is a prescription medicine used to treat adults with a type of cancer of the lining of the bladder called low-grade intermediate risk non-muscle invasive ...

(RTTNews) - UroGen Pharma Ltd. (URGN) said that the U.S. Food and Drug Administration accepted the New Drug Application or NDA for investigational drug UGN-102 (mitomycin) for intravesical solution.

Presents 18-month duration of response (DOR) data from the ENVISION study Analyzes the impact of tumor burden or focality in recurrent LG-IR-NMIBC, a substudy from ENVISION Reports ENVISION and ATLAS ...

Zusduri demonstrated a 72.2% 24-month response durability in LG-IR-NMIBC patients, leading to FDA approval as a non-surgical treatment option. The ENVISION trial enrolled 240 patients, focusing on ...

Determining an immunohistochemical profile to predict response to intravesical bacillus Calmette–Guérin (BCG) in patients with high-grade non-muscle invasive bladder cancer. This is an ASCO Meeting ...

The benefit-risk profile was favorable, supporting UGN-102 mitomycin gel as a nonsurgical alternative to TURBT in patients with recurrent low-grade, intermediate-risk non-muscle invasive bladder ...

PRINCETON, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and ...

Bladder cancer occurs when cancerous cells form in the tissues of the bladder, the hollow organ in your abdomen that stores ...